## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-133. Canceled.

134.-143. Canceled.

144. (new) A method of therapeutic or prophylactic treatment comprising the steps of: (a) implanting a silicon implant into a human or animal, the implant comprising a drug and resorbable mesoporous silicon, the drug being at least partly located in the pores of the porous silicon; and (b) allowing the porous silicon to erode.

145. (new) A method according to claim 144 wherein the implant comprises macroporous silicon.

146. (new) A method according to claim 144 wherein the drug is at least partly located in the silicon skeleton in which the pores are formed.

147. (new) A method according to claim 144 wherein the resorbable mesoporous silicon has a porosity between 2% and 80%.

148. (new) A method according to claim 147 wherein the resorbable mesoporous silicon has a porosity between 4% and 55%.

149. (new) A method according to claim 144 wherein the resorbable mesoporous silicon has a structure such that it is tissue compatible.

150. (new) A method according to claim 144 wherein in step (b) the resorbable mesoporous silicon erodes over an interval of between one month and two years.

- 2 -

CANHAM et al.
Appl. No. 09/647,599
August 15, 2003

- 151. (new) A method according to claim 144 wherein the implant has a largest dimension x, wherein  $0 < x \le 2$  mm.
- 152. (new) A method according to claim 144 wherein the drug is distributed through substantially the whole volume of the material of said implant.
  - 153. (new) A method according to claim 144 wherein the implant comprises substantially entirely resorbable mesoporous silicon.